Howard Berman

Howard Berman is recorded as Board Member at Atea Pharmaceuticals, Inc. (AVIR) since January 1, 2025 and Chairman at Coya Therapeutics, Inc. (COYA) since November 1, 2024. The newest filing on record that lists Howard Berman as Board Member at Atea Pharmaceuticals, Inc. (AVIR) is dated April 27, 2026. The newest filing on record that lists Howard Berman as Chairman at Coya Therapeutics, Inc. (COYA) is dated May 16, 2025. Coya Therapeutics, Inc. reported in an 8-K filed April 2, 2026 that Howard Berman resigned as board of directors, effective April 1, 2026. Coya Therapeutics, Inc. reported in an 8-K filed April 2, 2026 that Howard Berman resigned as Executive Chairman, effective April 1, 2026. Coya Therapeutics, Inc. reported in an 8-K filed October 31, 2024 that Howard Berman was appointed Executive Chairman, effective November 1, 2024. Equibles holds 5 filed executive changes naming Howard Berman; each is listed under recent activity with its source filing. The proxy statement of Coya Therapeutics, Inc. reports total compensation of $1,471,701 for Howard Berman in fiscal 2025, including a base salary of $436,800. Disclosed compensation is on record for 5 fiscal years. Atea Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Coya Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Atea Pharmaceuticals, Inc. includes Jean-Pierre Sommadossi (CEO and Board Member), Andrea Corcoran (CFO), Wayne Foster (Chief Accounting Officer) and 7 others.